The most common adverse events were hyperglycaemia ( 21 [ 33 % ] for treatment with 40 mg pasireotide , 19 [ 31 % ] with 60 mg pasireotide , and nine [ 14 % ] with active control ) , diabetes ( 13 [ 21 % ] , 16 [ 26 % ] , and five [ 8 % ] ) , and diarrhoea ( ten [ 16 % ] , 12 [ 19 % ] , and three [ 5 % ] ) ; most were grade 1 or 2 in severity .